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Abstract: Background: The developing lung is uniquely susceptible and may be at increased risk of
injury with exposure to e-cigarette constituents. We hypothesize that cellular toxicity and airway
and vascular responses with exposure to flavored refill solutions may be altered in the immature
lung. Methods: Fetal, neonatal, and adult ovine pulmonary artery smooth muscle cells (PASMC) were
exposed to popular flavored nicotine-free e-cigarette refill solutions (menthol, strawberry, tobacco,
and vanilla) and unflavored solvents: propylene glycol (PG) or vegetable glycerin (VG). Viability
was assessed by lactate dehydrogenase assay. Brochodilation and vasoreactivity were determined on
isolated ovine bronchial rings (BR) and pulmonary arteries (PA). Results: Neither PG or VG impacted
viability of immature or adult cells; however, exposure to menthol and strawberry flavored solutions
increased cell death. Neonatal cells were uniquely susceptible to menthol flavoring-induced toxicity,
and all four flavorings demonstrated lower lethal doses (LD50) in immature PASMC. Exposure to
flavored solutions induced bronchodilation of neonatal BR, while only menthol induced airway
relaxation in adults. In contrast, PG/VG and flavored solutions did not impact vasoreactivity with the
exception of menthol-induced relaxation of adult PAs. Conclusion: The immature lung is uniquely
susceptible to cellular toxicity and altered airway responses with exposure to common flavored
e-cigarette solutions.
Keywords: electronic cigarettes; electronic cigarette flavorings; toxicity; immature lung;
lung development
1. Introduction
Electronic nicotine delivery devices (ENDS), or electronic cigarettes, have been developed as a safer
and less toxic substitute to smoking. Use of these products is growing rapidly, and predictions based
on current sales suggest that consumption of e-cigarettes could surpass that of conventional cigarettes
within the next decade with estimates of a $50 billion global market by 2025 [1,2]. While established
smokers can avoid known tobacco toxicities with e-cigarette use, vulnerable populations may exist
who are more susceptible to exposure. Pregnant women as well as parents and caregivers of infants
may rationalize a switch to these products to reduce risks for children. Indeed, studies have shown that
e-cigarette use is increasing sharply among women of reproductive age and that they are perceived by
many as safer alternatives during pregnancy [3–6]. An online survey of 455 pregnant women recruited
from a national website survey service (Amazon Mechanical Turk) identified higher rates of vaping as
compared to smoking with 6.5% of respondents reporting sole use of e-cigarettes, 5.6% reporting sole
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use of conventional cigarettes, and an additional 8.4% reporting use of both products [7]. A clinical
survey performed at a university-based clinic (Little Rock, Arkansas) implied even higher rates in an
obstetrical cohort with 11.9% reporting current e-cigarette use. [8]. Oncken et al. similarly found that
14% of participants in a smoking cessation trial reported use of e-cigarettes during pregnancy, most
commonly to quit [9]. Despite these perceptions and practices, the impact of exposure to e-cigarettes on
the fetal and the newborn population during this vulnerable period of development remains unknown.
Clinical studies to investigate effects of in utero and postnatal secondhand exposures are challenged by
highly variable products and patterns of use, complex ethics, and issues with compliance.
While data from clinical studies and animal models suggest e-cigarettes reduce risks of adult
tobacco-related disease [10,11], concerns remain for their impact with fetal or neonatal exposures [12–14].
Although the consequences of pre and postnatal nicotine exposure have been characterized (including
concerns for compromised pulmonary development and lung function as well as adverse neurocognitive
and behavioral outcomes [15–21]), little is known regarding the impact of early exposure to the numerous
additional constituents of e-cigarette refill solutions, including propylene glycol (PG), vegetable glycerin
(VG), and commonly used flavorings. Studies in undifferentiated embryonic cells raised concerns
for increased susceptibility to cell death with exposure to e-cigarette solutions [22]. Specifically,
nicotine and flavored e-cigarette refill solutions induced greater cytotoxicity in undifferentiated human
embryonic stem cells (hESC) as well as mouse neural stem cells (mNSC) as compared to more mature
human pulmonary fibroblasts (hPF).
Indeed, the unique characteristics of the immature lung may render the fetus and the newborn
more vulnerable to injury with exposure to toxicants. Compromised antioxidant defenses and altered
inflammatory responses can contribute to age-dependent susceptibilities [23–25]. As an example,
we previously demonstrated that supraphysiologic oxygen induces exaggerated mitochondrial
oxidant stress as well as increased cell death in neonatal as compared to adult lung cells [26].
In addition, compromise of alveolar and vascular development observed with neonatal hyperoxia is
developmentally regulated with greater evidence of lung injury induced by early as opposed to late
exposure [27].
Specific attributes of fetal and newborn physiology further influence susceptibility to chemical
exposures [28]. Increased respiratory rates in newborns can increase environmental exposure to
secondhand aerosols. Lower metabolic rates, variable enzymatic activity, decreased concentration
of plasma binding proteins, as well as reduced renal and biliary excretion can all further impact
chemical exposures in a fetus or a newborn. A higher percentage of water versus body fat in the fetus
and the newborn provide opportunity for lipophilic substances to accumulate while water soluble
compounds can also concentrate in utero, as these chemicals are commonly excreted into amniotic fluid
with reabsorption through the immature fetal skin. As a prime example, higher nicotine levels have
been observed in fetal tissue as compared to maternal blood [29]. Collectively, these physiologic and
cellular mechanisms impact bioavailability and may exaggerate risks of toxicity with fetal or neonatal
exposures to the chemical constituents present in e-cigarettes.
Despite the common presence of added flavoring chemicals in e-cigarette products, little is known
regarding the safety and the long-term health effects associated with aerosolized exposure to these
constituents [30–32]. The concentrations of flavor chemicals in e-cigarette fluids are sufficiently high for
toxicity to be of concern both for adults who use these products and for children who may be exposed in
utero or via secondhand inhalation. Studies have documented that flavorings make up more than 1–4%
(10–40 mg/mL) of e-cigarette refill solution volume, whereas nicotine typically ranges from 0.6–2.4%
(6 to 24 mg/mL) [33]. Online vaping forums suggest that use of 5 mL per day of flavored e-liquids
would be common, resulting in significant cumulative exposure with chronic use [34]. While the
extent to which these chemicals are delivered to the fetus and the newborn remains unknown, in utero
exposures are a valid concern, with a murine model identifying alterations in the hippocampus of
offspring exposed to nicotine-free flavored e-cigarettes during gestation [14]. Additionally, flavoring
chemicals that are not effectively retained in the user’s lungs would be exhaled by e-cigarette users,
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leading to concerns for secondhand exposure of newborn and infants in proximity of caregivers who
vape [35–37].
Flavoring solutions commonly contain a mixture of numerous chemicals; as an example, analysis
of 28 representative e-liquids identified over 140 different flavoring chemicals present in one published
panel [38]. While many of these chemicals are commonly ingested with food products and have been
certified as “Generally Recognized as Safe” (GRAS) by the Flavoring and Extracts Manufacturers
Association (FEMA), this designation is in reference to safety with ingestion or topical exposure only
and would not apply to inhalation. Indeed, the bioavailability and the consequence of exposure with
vaping of flavoring chemicals deemed as safe for ingestion remain unknown.
With growing appreciation for toxicity of flavoring chemicals [30,32,39–42] and a specific concern
for the consequences of exposure on the vulnerable developing lung, we sought to determine the
relative toxicity and the impact on physiologic responses in immature lungs cells and tissue exposed to
popular nicotine-free e-cigarette flavored solutions [34,43]. Unique access to fetal, newborn, and adult
ovine pulmonary cells lines as well isolated neonatal and adult ovine lung tissue allowed evaluation of
developmental susceptibility. We hypothesized that the fetal and the neonatal lung would be more
vulnerable to flavoring solution-induced toxicities and that airway and pulmonary vascular response
with exposure may also be developmentally regulated.
2. Materials and Methods
2.1. Flavored E-Cigarette Refill Solutions
Convenience samples of flavored solutions used for these studies were labeled as made by Ecto
World (https://www.ectoworld.com) and purchased locally from a single vender (Cloud 9 Smokes and
Vapors, 476 Elmwood Ave, Buffalo, NY, USA). Products were labeled as Menthol, Vanilla Cupcake,
American Tobacco, and Strawberry Blast with 0 mg nicotine. These four were selected as a pilot to
both assess actual products in use and to include a range of popular flavorings based on published
literature [34,38,43]. Non-targeted analysis of e-liquids was performed as previously published using
gas chromatography–mass spectrometry (GCMS) to determine constituents and confirm that samples
were nicotine free [30]. Briefly, 10 µL of each sample was diluted with 1 mL methanol (Fisher Scientific;
Waltham, MA) and analyzed by GCMS using an Agilent 7890B GC and an Agilent 5977A MS (Santa
Clara, CA). An HP−5 30 m × 0.320 mm × 0.25 m capillary column (Agilent) with a flow rate of helium
of 1.7 mL/min was utilized. Temperature of the injector and the detector was 250 ◦C, and the column
temperature increased from 110 to 250 ◦C (10 ◦C/min) with a hold for 1 min. The injection volume was
1 µL with a split ratio of 40:1. Qualitative analysis of the flavored liquids was carried out using the
NIST 14 Mass Spectral Library (U.S. Department of Commerce) as well as the Flavors and Fragrances
of Natural and Synthetic Compounds 3 flavoring library.
2.2. Cell Culture
Primary pulmonary artery smooth muscle cell (PASMC) cultures were prepared from
intrapulmonary arteries collected from healthy 125 (gestational) day fetal, 2 day newborn lambs, and
adult ewes as previously published [44]. Numerous publications support our use of this large animal
model, as ovine pulmonary development and physiology parallel human, while cellular metabolism
and signaling in isolated tissue and cell lines correlate with findings in human disease [44–53].
For toxicity studies, cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 10%
fetal bovine serum (FBS), 2 mM l-glutamine and 100 units/mL penicillin, 100 mg/mL streptomycin (P/S)
under standard cell culture conditions (37 ◦C with 5% CO2). All experiments were carried out between
passages 3 and 8. Cells were seeded onto 12 well plates at approximately 8000 cells per cm2 and grown
to 60–70% confluency. Fetal, newborn, and adult PASMC were subsequently synchronized by transfer
to serum-free DMEM + P/S for one hour prior to treatment in parallel with select nicotine-free flavored
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solutions, pure propylene glycol (PG), or pure vegetable glycerin (VG) (Fisher Scientific, NH) at 1:100,
1:1000, or 1:10,000 dilutions. Cell death assays were performed following 24 h incubation.
2.3. Cell Death
Cell death was determined using a lactate dehydrogenase (LDH) assay (Biovision, San Francisco,
CA). Using an enzymatic coupling reaction, LDH was quantified in the supernatant and the tritonized
cell lysate. LDH activity was determined by spectrophotometric reading at OD450. Percent cell death
was calculated as concentration in supernatant/concentration in lysate × 100. Dilution at which 50%
cell death would occur (lethal dose or LD50) was calculated assuming linear dose dependency (from
studies in which testing of two doses concurrently was possible) with extrapolation of values out to a
1:10 dilution.
2.4. Isolated Airway and Vessel Studies
Airways and vessels from pregnant ewe and newborn lambs were collected following sacrifice
of animals utilized for a separate experimental protocol evaluating transitions at birth. For those
studies, newborn lambs were delivered by c-section as part of an Institutional Animal Care and Use
Committee at the State University of New York at Buffalo approved protocol (PED10085N). C-section
was performed under 4% isoflurane anesthesia. Newborn lambs were ventilated for 4–6 h prior to
sacrifice, during which time they received fentanyl titrated from 0–5 mcg/kg/h. Ewes and lambs were
euthanized following delivery and completion of the study with pentobarbital (100 mg/kg). Animals
were exposed to purified air or oxygen only prior to sacrifice.
The intrapulmonary arteries (PA) and the fifth generation bronchial rings (BR) were dissected,
washed in Krebs solution (NaCl 119 mM, KCl 5.4 mM, CaCl2 2.5 mM, KH2PO4 0.6 mM, MgSO4 1.2 mM,
NaHCO3 25 mM, and glucose 11.7 mM), and hung in vessel baths aerated with 21% O2 and 6% CO2 to
achieve a pH of 7.4, as described previously [50]. The samples were mounted and stretched to a passive
tension of 800 mg (PA) and 1000 mg (BR) to optimize reactivity to experimental agents. A continuous
recording of isometric force generation was obtained by tying each vessel ring to a force displacement
transducer (model UC2, Statham Instruments, NY) that was connected to a recorder (Gould Instrument,
OH). PA were pretreated with propranolol (10−6 M) to block the beta adrenergic effects and constricted
with increasing titrations (10−8 to 10−5 M) of norepinephrine (propranolol and NE, Sigma Aldrich,
MO). BR were constricted with increasing titrations (10−8 to 10−5 M) of 5-hydroxytryptamine (5-HT,
Sigma Aldrich, MO).
To study responses to flavored solutions, PA and BR were preconstricted with half maximal
effective concentration (EC50) of NE or 5-HT followed by treatment with a flavoring or 50/50 PG/VG at
a 1:1000 dilution with companion preparation (5-HT or NE) alone used as time controls. Preconstriction
to EC50 allowed tested e-liquids to further constrict or relax as is physiologically relevant. Following
experimental treatment, PA and BR were washed with Krebs solution. Maximal contractile response to
118 mM/L of potassium chloride (KCl) was obtained. Wet tissue weights were obtained at the end
of each experiment, and constriction responses were normalized to tissue weight and compared as
percentages of relaxation of the EC50 constriction. Data were analyzed as force of constriction per unit
of tissue weight (grams of force per gram of tissue weight) of the vasoconstrictor agent. Response to
flavored solutions was expressed as a percentage of maximal constriction of 5-HT or NE.
2.5. Statistical Analysis
Continuous variables were analyzed using a Student’s t-test or ANOVA as appropriate with
Tukey’s post hoc analysis. A p value of ≤0.05 was considered statistically significant. For cellular
experiments, 2–3 wells on a plate were treated for each condition, and the average result considered one
n with >6 n from independent cell platings for all studies. For vessel and airway reactivity, replicate
tissues from 4 adult and 6 neonatal lambs were studied.
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3. Results
3.1. Chemical Analysis of Flavored Liquid Solutions
Non-targeted GCMS analysis confirmed that the Ecto flavored solutions did not include nicotine
in two batches of the four flavors used in the study. The two batches were purchased nine months
apart with the second batch being nine months old at chemical analysis. Consistent with prior
publications [33,38], non-targeted GCMS analysis identified a large number of chemicals present in
each of the four samples with variability between batches (Table 1).
Flavorings common to all four included benzophenone (CAS 119-61-9), hydroxyacetone (CAS
116-09-6), and ethyl maltol (CAS 11-8-4940). Unique flavoring chemicals were identified with each
flavored solution; however, there was significant overlap in chemicals present in the four studied.
Menthol had the most unique chemical flavorings present while tobacco had the least (Figure 1 and
Supplementary Table S1). GCMS did not allow for quantification of the specific chemicals present.
Table 1. Chemical analysis by gas chromatography–mass spectrometry (GCMS). GCMS was performed
on two batches of Ecto flavoring solutions, confirming absence of nicotine but chemical variability with
differences in the number of chemicals present in batches of the same flavored solution.
Menthol Strawberry Tobacco Vanilla
All chemicals
Batch 1 76 83 37 77
Batch 2 72 72 39 66
Propylene glycol (PG) Positive Positive Positive Positive
Vegetable glycerin (VG) Positive Positive Positive Positive
Nicotine Negative Negative Negative Negative
Flavoring chemicals
Batch 1 44 39 12 43
Batch 2 35 34 14 34
% flavorings 53% 47% 34% 54%
Major flavoring
chemicals detected
(±)-Menthol
Pulegone
Alpha-pinene
Anethol
(E)-Cinnamyl acetate
Linalool
Methyl cinnamate
Benzyaldehyde
Isovaleraldehyde
Linalool
Beta-damascene
Isoamyl butyrate
Dihydrojasmone
lactone
Para-anisaldehyde
Acetoin
Fruity ketal
Vanillin
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Figure 1. Flavoring composition f four popular flavored refill solutions. GCMS performed on flavored
solutions identified notabl overlap f flavoring chemicals present with three present in all four
analyzed and an additional 16 present in two or more. Analysis also identified a wide range i the
number of unique flavorings present from three in tobacco to 34 in menthol. See the Supplemental
Table S1 for specific chemicals.
3.2. Cell Toxicity Studies
As pulmonary blood vessels actively promote alveolar development and contribute to the
maintenance of alveolar structures throughout postnatal life [54], we chose to evaluate the toxicity of
flavored solutions on pulmonary artery smooth muscle cells (PASMC). To determine relative toxicity
in immature versus mature cells, fetal, neonatal, and adult PASMCs were exposed to a select panel of
flavored solutions, pure PG, or VG for 24 h at variable dilutions (1:100, 1:1000, 1:10,000). Cell death was
flavoring dependent, with the greatest to the least toxicity observed with menthol, strawberry, tobacco,
and vanilla flavorings. Exposure to 1:100 dilution of menthol and strawberry solutions induced
significant cell death in fetal, neonatal, and adult cells (control: 15.2 ± 3.5, 13.6 ± 2.7, 15.6 ± 2.9%;
menthol: 57.9 ± 6.2, 74.5 ± 4.9, 46.3 ± 7.7%; strawberry: 47.6 ± 6.2, 47.2 ± 5.5, 44.8 ± 7.9% for fetal,
neonatal and adult PASMC, respectively). Immature cells were more susceptible to menthol toxicity
with the greatest cell death documented in neonatal cells (Figure 2A). In contrast, exposure to tobacco
and vanilla solutions did not significantly impact viability as compared to untreated controls. In
addition, treatment with unflavored, nicotine-free VG and PG resulted in no significant increase in
cell death (Figure 2B), implicating additional flavoring or non-flavoring chemicals present in the refill
solutions for the death observed in Figure 2A. Calculated LD50s suggested increased susceptibility to
flavored solutions in immature PASMC as compared to adults, with lower calculated concentration
noted for fetal and neonatal PASMCs in all four tested flavorings as compared to adults (Table 2).
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Figure 2. Exposure to select flavored solutions induced cell death in pulmonary artery smooth muscle
cells (PASMC). PASMC isolated from fetal, neonatal, and adult ovine lungs were treated with variable
concentrations of flavored solutions or pure vegetable glycerin (VG)/propylene glycol (PG) for 24 h.
(A) The 1:100 dilution of menthol and strawberry resulted in significant increase in cell death as
compared to untreated controls (* p < 0.05). Immature cells were more susceptible to menthol toxicities
(† p < 0.05 as compared to adult). (B) The 1:100 and the 1:10,000 VG and PG exposure did not result in
significant increase in cell death. Data are presented as mean + SEM. n ≥ 6.
Table 2. Immature PASMC demonstrated increased susceptibility to flavored solutions by calculated
LD50s. Cell death documented by lactate dehydrogenase (LDH) assay at variable dosing was used to
calculate concentration at which 50% cell death would occur (lethal dose or LD50). Lower LD50s were
noted for fetal and neonatal cel s onsist nt with i cr ased susceptibility.
Fetal Neonatal Adult
Menthol 0.62 0.59 1.62
Strawberry 1.14 1.34 2.15
Tobacco 2.23 2.95 5.60
Vanilla >10 6.61 >10
PG >10 >10 >10
VG >10 7.19 >10
3.3. Airway and Vessel Reactivity Studies
Bronchial Rings: To determine whether airway response to flavored solutions was also
developmentally regulated, both neonatal and adult intrapulmonary bronchial rings (BR) were
preconstricted with EC50 doses of 5-HT. Once plateau contraction was achieved, BR were exposed
to nicotine-free, unflavored 50%/50% PG/VG as well as selected flavored solutions at 1:1000 dilution.
Treatment with PG/VG did not impact EC50 constriction of neonatal or adult BR (92.6 ± 3.5% and
98.4 ± 5.1% constriction of time control, respectively). Treatments with 1:1000 dilution of menthol,
strawberry, vanilla, and tobacco e-liquids all resulted in significant airw y relaxation in neon tal BR
as com ar d to untreated time controls (menthol: 8.0 ± 9.1; strawberry: 88.2 ± 2.8; vanilla: 54.6 ± 13.2;
tobacco: 69.7 ± 8.2% constriction of neonatal tim control) (Figure 3A). In contrast, exposure to the same
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concentrations of 1:1000 dilution of strawberry, vanilla, and tobacco did not impact airway relaxation in
adult BRs, although some relaxation with menthol was observed (menthol: 85.5 ± 2.2% constriction of
adult time control). Neonatal airway bronchodilation with exposure to menthol and tobacco flavored
solutions was significantly greater than that observed in adult BR, with marked bronchodilation noted
with menthol (Figure 3B).
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Figure 3. Flavored solutions induced greater bronchodilation in newborn as compared to adult bronchial
rings. Bronchial rings (BR) isolated from neonatal and adult ovine lung were treated with flavored
solutions at 1:1000 dilution. (A) Menthol, strawberry, vanilla, and tobacco flavorings all induced
bronchodilation of neonatal BR, while only menthol induced bronchodilation in adults (# p < 0.05 as
compared to time control). Neonatal airway demonstrated significant decrease as compared to adult
with both menthol and tobacco exposure (* p < 0.05 as compared to adult). Data are presented as mean
+ SEM. n = 3–8. (B) Representative tracing demonstrating neonatal and adult responses in BR treated
with menthol flavoring (top) as compared to untreated (time control).
Contraction to EC50 5-HT elicited a force of 103 ± 14 g/g with a maximum constriction with KCl of
171 ± 23 g/g in adult BRs. Similarly, neonatal constriction to 5-HT was 54 ± 12 g/g with a maximum
constriction with KCl of 98 ± 19 g/g. These data support comparable contractions, as 5-HT elicited 60%
and 55% of max contraction for neonatal and adult BR, respectively.
Pulmonary Arteries: To evaluate pulmonary vascular response to flavored refill solutions, neonatal
and adult pulmonary arteries (PA) were preconstricted to EC50 with NE. Once stable constriction
was obtained, PA were similarly treated with 1:1000 nicotine-free, unflavored 50%/50% PG/VG and
selected flavored solutions. The 1:1000 dilution of PG/VG did not impact vasoconstriction in either
the neonate or the adult (101.4 ± 6.6 and 98.9 ± 2.4% constriction for neonate and adult, respectively).
While comparable dosing of flavored solutions resulted in relaxation of bronchial rings, no significant
change was noted with exposure of neonatal or adult PA to 1:1000 dilution of strawberry, vanilla, or
tobacco. However, treatment with 1:1000 dilution of menthol induced relaxation of adult but not
neonatal PA (85.5 ± 2.2 and 102.6 ± 3.2% constriction of time control for adult and neonate) (Figure 4).
Contraction to NE after propranolol elicited a force of 512 ± 6 g/g with a maximum constriction
with KCl of 538 ± 53 g/g in adult PAs. Similarly, neonatal constriction to NE was 126 ± 37 with a
maximum constriction with KCl of 148 ± 49 g/g. These data support comparable contractions, as NE
elicited 95% and 85% of max contraction for neonatal and adult PA, respectively.
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Figure 4. Effect of flavored solutions on vasodilation in newborn and adult pulmonary arteries (PA).
The 1:1000 dilution of strawberry, vanilla, and tobacco flavored solutions did not impact vascular
constriction in neonatal or adult PA. However, exposure to 1:1000 dilution of menthol flavoring resulted
in significant relaxation of adult but not neonatal PA (# p < 0.05 as compared to time control, * p < 0.05
as compared to adult PA). Data are presented as mean + SEM. n = 3–8.
4. Discussion
Our data suggest that the fetal and the neonatal lung may be at increased susceptibility to toxicity
with exposure to flavored e-cigarette solutions and that physiologic responses to these common
additives may also be altered in the immature lung. While flavored solutions have previously been
shown to be harmful to lung epithelial cells in some but not all in vitro models [30–32,55], these
studies are the first to identify a developmental susceptibility with exposure of differentiated lung
cells. Further, our results are novel in demonstrating that physiologic response to e-cigarette flavoring
solutions may also be developmentally regulated.
GCMS analysis identified a large number of non-flavoring and flavoring chemicals present within
each of the solutions with notable differences in products purchased nine months apart. While these
differences may in part be attributed to aging and chemical decomposition, our data more likely
represent the variability within products produced by a specific vendor [22]. Batch variability has been
well described and may account for some of the range in responses that we saw in our experiments
as well.
We further noted a wide range of toxicity with exposure to a limited panel of flavored solutions.
Both menthol and strawberry were noted to be highly toxic, consistent with prior publications [30,56].
While Bahl et al. suggested that the number of peaks on high-performance liquid chromatography
(HPLC) correlate with cytotoxicity [22], we noted a comparable number of total and flavoring chemicals
(by GCMS) in both toxic and non-toxic products. Importantly, as no nicotine was detected in all tested
products, the observed findings can be attributed to the added chemicals in flavoring solutions.
Of interest, while only two of four flavorings demonstrated significant toxicity at a 1:100 dilution,
all four flavorings induced bronchodilation in neonatal bronchial rings at a 1:1000 dilution with
limited or no impact on adult airway constriction at the same dose. As menthol has previously been
shown to inhibit airway smooth muscle contraction in tracheal tissue isolated from guinea pigs and
rats [57,58], we suspected all four flavoring samples might include some quantity of menthol or one
of its chemical derivatives. However, GCMS did not confirm this suspicion with identification of
(±)-menthol, (±)-menthone, (-)-menthone only in the product referred to as menthol, indicating that
additional flavoring chemicals are capable of inducing relaxation of neonatal airways.
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Bronchodilation in the neonatal airways suggests that newborns and infants in proximity to
secondhand flavored e-cigarette vapors may be at risk of exaggerated exposure to a higher concentration
of these and additional aerosolized chemicals (including nicotine when present) via increased delivery
to the alveoli. Increased minute ventilation in infants would further facilitate the delivery of these
aerosolized chemicals, compounding concerns for risk of toxicity in the immature lung.
Vaporized e-cigarette solutions and flavoring chemicals have been shown to contain notable
quantities of potentially toxic reactive oxygen species (ROS) [32,59]. Chemicals present in flavored
refill solutions may also be capable of inducing intracellular oxidative stress with absorption.
The developmental susceptibility to flavoring-induced toxicity and bronchodilation that we observed
in these studies may reflect compromised antioxidant capacities present in the immature lung [23],
as both cell death and airway responses are mediated by ROS [60–62]. Alternatively, altered cellular
metabolism, variable cellular absorption, or a difference in the immature inflammatory response [25]
could contribute to developmentally regulated responses.
While 1:1000 dilution of each of our studied e-liquids elicited bronchodilation in the newborn
airway, this dilution did not impact the pulmonary vasculature with the exception of vasodilation of
adult pulmonary arteries with exposure to menthol flavored solutions. Menthol is a common and
highly popular flavoring with both vaping and conventional cigarettes, with surveys implying that
27% of smokers report use of mentholated products [63]. Pulmonary vasodilation (as observed in the
adult PAs) with menthol inhalation could facilitate absorption of e-cigarette constituents including
nicotine, raising concern for potential exacerbation of toxicities and increased gestational exposure.
Indeed, some studies suggest that mentholated products may be associated with increased pulmonary
pathology [64,65].
While our data are novel in evaluating the consequences of exposure in fetal and neonatal
pulmonary cells as well as immature lung tissue, there are several limitations to these studies. Notably,
e-cigarette refill solutions were added directly to cell cultures or tissue perfusate, resulting in an
exposure that failed to include toxic products generated with heating and aerosolization, avoided
the process of thermal degradation, and was potentially at an inaccurate pH [66]. While analytical
evaluation demonstrated highly efficient transfer of flavoring chemicals to aerosol (mean transfer 98%
at both 3V and 5V) [67], unique chemicals produced with vaping of flavored refill solutions are not
represented in these studies. Further, variable temperatures, voltage, devices, and puffing patters have
all been shown to modify aerosol toxicity and were not explored [68]. We acknowledge that these
limitations impact the interpretation of these studies and fail to meet optimal modeling suggested by
Behrsing et al. [69]. We utilized direct exposure with the technical challenges of delivering aerosolized
product into the tissue perfusate and to cultured PASMCs.
In addition, our study does not distinguish the effect of specific flavoring chemicals or eliminate
the potential contribution of impurities limiting our conclusions. Future studies investigating the
specific chemicals of interest individually with known purity and concentrations present in refill
solutions would be indicated. We also acknowledge that our small panel fails to characterize the
extensive library of now over 7000 unique flavors on the market and may not be generalizable to other
e-cigarette products [70]. Finally, the toxicity of the flavoring solutions was not contextualized with
comparison to tobacco; ultimately, these products may represent a safer alternative to smoking.
We are further limited by the lack of data regarding typical concentration of flavoring chemicals
that lung cells, pulmonary tissue, and a fetus might be exposed to. Online vaping forums suggest that
use of 5 mL per day of flavored refill solutions would be common [33]. Our dosing range maxed at
1% to model some degree of dilution and was based on rationale provided in other publications [56].
Specifically, based on particle size, the predicted deposition of e-cigarette aerosol in the lungs is
15–45% [71]. Given that the airway surface liquid volume in the lung is approximately 3 mL [56],
vaping of 10 mL would lead to a dilution of 33–60%, suggesting that our experimental dosing of 0.1–1%
may be in reasonable range for PASMC and tissue exposure. While the specific concentrations with
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fetal exposure remain unknown, recent publications have demonstrated that flavoring chemicals can
indeed impact fetal development [14].
Finally, while these studies are novel in comparing toxicity and physiologic responses with
exposure in both neonatal and adult models, responses were limited to isolated cells and tissue.
Our data suggesting a developmental susceptibility to commonly used flavored solutions advocate for
further evaluation of these chemicals by way of in vivo exposure to the aerosolized product.
5. Conclusions
Gestational and postnatal exposure to electronic cigarettes represents rapidly growing threat
to the fetal and the newborn population. Use of added flavorings with vaping has far out-paced
our understanding of their implications for public health. Our data suggesting a developmental
susceptibility with exposure to common flavoring solutions argue the critical need for further thoughtful
evaluation of these products.
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